Silencing of Lactotransferrin expression by methylation in prostate cancer progression

被引:40
|
作者
Shaheduzzaman, Syed
Vishwanath, Anu
Furusato, Bungo
Cullen, Jennifer
Chen, Yongmei
Banez, Lionel
Nau, Martin
Ravindranath, Lakshmi
Kim, Kee-Hong
Mohammed, Ahmed
Chen, Yidong
Ehrich, Mathias
Srikantan, Vasantha
Sesterhenn, Isabell A.
McLeod, David G.
Vahey, Maryanne
Petrovics, Yorgy
Dobi, Albert
Srivastava, Shiv
机构
[1] Uniformed Serv Univ Hlth Sci, US Mil Canc Inst, Dept Surg, Ctr Prostate Dis Res, Rockville, MD 20852 USA
[2] Armed Forces Inst Pathol, Dept Genitourinary Pathol, Washington, DC 20306 USA
[3] Walter Reed Army Med Ctr, Urol Serv, Washington, DC 20307 USA
[4] NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA
[5] WRAIR, Div Retrovirol, Rockville, MD USA
[6] SEQUENOM Inc, San Diego, CA USA
关键词
LTF; downregulation; methylation; PSA doubling time; chemoprevention;
D O I
10.4161/cbt.6.7.4327
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cancer cells gain selection advantages by the coordinated silencing of protective and by the activation of cell proliferation/cell survival genes. Evaluations of epithelial cell transcriptome of benign and malignant prostate glands by laser capture microdissection (LCM) identified Lactotransferrin (LTF) as the most significantly downregulated gene in prostate cancer (CaP) cells (p < 10(-6)). Frequent downregulation, significant association of LTF with PSA recurrence-free survival in CaP patients and the established anti-tumorigenic effects of LTF in experimental cancer models have provided impetus to evaluate LTF expression features and mechanisms in CaP specimens. Methods: LTF mRNA expression analysis was performed in LCM derived benign and malignant prostate epithelial cells by using Affymetrix GeneChip and QRT-PCR. LTF protein expression was assessed in tissue specimens by immunohistochemistry and in serum samples from CaP patients compared to healthy male control by using ELISA. Mechanism of LTF downregulation was analyzed in 5-azadeoxycytidine treated LNCaP and LAPC4 cells using MALDI-TOF MS. Proliferation and cell cycle analysis of CaP cells by FACS flow cytrometry was assessed in LNCaP cell cultures. Results: Quantitative analysis of LTF mRNA expression in tumor cells revealed marked downregulation of LTF with significant associations to decreased PSA recurrence-free survival of CaP patients (n = 100, p <= 0.0322). Moreover, low levels of LTF protein expression was observed in tumor tissues as well as in sera from CaP patients (p <= 0.0001). LTF promoter downstream CpG island methylation was found in LNCaP and LAPCA cells. Furthermore, replenishing of LTF by supplementing growth media with LTF protein resulted in reduced cell growth. Cell cycle analysis revealed robust increases in apoptosis in response to LTF treatment. Conclusion: This study highlights the potential for LTF in chemoprevention and to become a biologically relevant prognostic marker of CaP, suggesting that silencing of the LTF gene may be causally linked to CaP progression.
引用
收藏
页码:1088 / 1095
页数:8
相关论文
共 50 条
  • [41] The APC gene: DNA methylation and protein expression in prostate cancer
    Abramovic, I.
    Pezelj, I.
    Kulis, T.
    Bojanac, A. Katusic
    Ulamec, M.
    Bulimbasic, S.
    Sincic, N.
    FEBS OPEN BIO, 2022, 12 : 99 - 99
  • [42] ERG lysine methylation promotes prostate cancer progression in ERG transgenic mice
    Zoma, Marita
    Shinde, Dheeraj
    Albino, Domenico
    Mosole, Simone
    Sgrignani, Jacopo
    Cavalli, Andrea
    Catapano, Carlo V.
    Carbone, Giuseppina M.
    CANCER RESEARCH, 2018, 78 (13)
  • [43] Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer
    Li, LC
    Zhao, H
    Nakajima, K
    Oh, BR
    Ribeiro, LA
    Carroll, P
    Dahiya, R
    JOURNAL OF UROLOGY, 2001, 166 (02): : 705 - 709
  • [44] Expression of Cancer/Testis Antigens in Prostate Cancer Is Associated With Disease Progression
    Suyama, Takahito
    Shiraishi, Takumi
    Zeng, Yu
    Yu, Wayne
    Parekh, Nehal
    Vessella, Robert L.
    Luo, Jun
    Getzenberg, Robert H.
    Kulkarni, Prakash
    PROSTATE, 2010, 70 (16): : 1778 - 1787
  • [45] CXXC5 expression in prostate cancer: implications for cancer progression
    Benedetti, Ines
    De Marzo, Angelo M.
    Geliebter, Jan
    Reyes, Niradiz
    INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2017, 98 (04) : 234 - 243
  • [46] Prostate-specific membrane antigen expression as a predictor of prostate cancer progression
    Perner, Sven
    Hofer, Matthias D.
    Kim, Robert
    Shah, Rajal B.
    Li, Haojie
    Moeller, Peter
    Hautmann, Richard E.
    Gschwend, Juergen E.
    Kuefer, Rainer
    Rubin, Mark A.
    HUMAN PATHOLOGY, 2007, 38 (05) : 696 - 701
  • [47] PTHrP expression promotes prostate cancer progression in bone.
    Barken, I
    Burton, DW
    Geller, J
    JOURNAL OF INVESTIGATIVE MEDICINE, 2003, 51 : S118 - S118
  • [48] The significance of LMO2 expression in the progression of prostate cancer
    Ma, S.
    Guan, X. Y.
    Beh, P. S. L.
    Wong, K. Y.
    Chan, Y. P.
    Yuen, H. F.
    Vielkind, J.
    Chan, K. W.
    JOURNAL OF PATHOLOGY, 2007, 211 (03): : 278 - 285
  • [49] SPINK1 Protein Expression and Prostate Cancer Progression
    Flavin, R.
    Hendrickson, W.
    Krunz, L.
    Judson, G.
    Lis, R.
    Bailey, D.
    Fiorentino, M.
    Finn, S.
    Martin, N.
    Stark, J.
    Pettersson, A.
    Sinnott, J.
    Penny, K.
    Fall, K.
    Giovannucci, E.
    Rubin, M.
    Kantoff, P.
    Stampfer, M.
    Loda, M.
    Mucci, L.
    MODERN PATHOLOGY, 2011, 24 : 192A - 192A
  • [50] PrLZ Expression Is Associated With the Progression of Prostate Cancer LNCaP Cells
    Li, Lei
    Zhang, Dong
    Zhang, Linlin
    Zhu, Guodong
    Sun, Yi
    Wu, Kaijie
    Wang, Xinyang
    He, Dalin
    MOLECULAR CARCINOGENESIS, 2009, 48 (05) : 432 - 440